BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $56,000 | -53.3% | 14,777 | 0.0% | 0.00% | – |
| Q1 2019 | $120,000 | +0.8% | 14,777 | 0.0% | 0.00% | – |
| Q4 2018 | $119,000 | +5.3% | 14,777 | 0.0% | 0.00% | – |
| Q3 2018 | $113,000 | +32.9% | 14,777 | 0.0% | 0.00% | – |
| Q2 2018 | $85,000 | +21.4% | 14,777 | 0.0% | 0.00% | – |
| Q1 2018 | $70,000 | -94.1% | 14,777 | -87.2% | 0.00% | -100.0% |
| Q4 2015 | $1,188,000 | -8.3% | 115,116 | +1.3% | 0.00% | -20.0% |
| Q3 2015 | $1,295,000 | -27.2% | 113,606 | -4.6% | 0.01% | -16.7% |
| Q2 2015 | $1,778,000 | +70.5% | 119,106 | +3.1% | 0.01% | +50.0% |
| Q1 2015 | $1,043,000 | -19.7% | 115,496 | +8.1% | 0.00% | -20.0% |
| Q4 2014 | $1,299,000 | +28.0% | 106,806 | +2.9% | 0.01% | +25.0% |
| Q3 2014 | $1,015,000 | -23.3% | 103,806 | 0.0% | 0.00% | -20.0% |
| Q2 2014 | $1,324,000 | +21.8% | 103,806 | +1.1% | 0.01% | +25.0% |
| Q1 2014 | $1,087,000 | +11.7% | 102,706 | -19.8% | 0.00% | 0.0% |
| Q4 2013 | $973,000 | – | 128,076 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |